Cyclacel Pharma (CYCC) Reports Q1 Loss of $0.38

Cyclacel Pharma (NASDAQ: CYCC) reported Q1 EPS of ($0.38), versus ($0.12) reported last year.

As of March 31, 2018, cash and cash equivalents totaled $21.7 million, compared to $23.9 million as of December 31, 2017. The decrease of $2.2 million was primarily due to net cash used in operating activities.

For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
• SPS Commerce hires Morgan Stanley to explore sale amid activist push - Reuters